Hi Quiltman,
My estimations researched a while ago was Tanovea cost 161 million USD and Galliprant ( canine osteoarthritis) cost 84 million USD. Both bought at the same time from another VM.
This was the costings Elanco paid before the spin off to Eli Lilly.
RA did say a while ago he could sell it for 200 million AUD . But, that probably means post Phase 3.
Hi Quiltman,My estimations researched a while ago was Tanovea...
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $86.55M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.5¢ | 18.5¢ | $330.4K | 1.741M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4071 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 24580 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |